{"id":"W4322775169","doi":"10.1158/1538-7445.sabcs22-pd11-09","title":"Abstract PD11-09: PD11-09 Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; Université de Sherbrooke; London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Internal medicine; Oncology; Triple-negative breast cancer; Tolerability; Cancer; Breast cancer; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001688049,0.001172141,0.001943036,0.001110399,0.001185118,0.0002323,0.001014244,0.0002755509,0.002390137],"category_scores_gemma":[0.001106116,0.001012859,0.0004084682,0.003755645,0.000774245,0.0007916078,0.0003869086,0.001323566,0.000479901],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004720462,"about_ca_system_score_gemma":0.00439464,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.03908156,"about_ca_topic_score_gemma":0.02489571,"domain_scores_codex":[0.9896407,0.0005155329,0.001692867,0.002744646,0.002555062,0.002851208],"domain_scores_gemma":[0.9915053,0.002174758,0.0005689294,0.002225442,0.0023232,0.001202433],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2139505,0.01639845,0.002126035,0.0009062869,0.007800426,0.003021115,0.01303595,0.007198283,0.03167997,0.00007450618,0.01312783,0.6906807],"study_design_scores_gemma":[0.6058969,0.03085737,0.04204991,0.006254388,0.002723789,0.0003669716,0.037992,0.008471557,0.1156615,0.009982748,0.1348172,0.004925736],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9454947,0.003607592,0.000345908,0.01188602,0.0007877836,0.01212443,0.02477176,0.0006392801,0.0003425888],"genre_scores_gemma":[0.9696946,0.003730762,0.0008422931,0.0002354431,0.001173376,0.01198452,0.002752075,0.000438171,0.009148752],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.685755,"threshold_uncertainty_score":0.9992322,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1129856912723048,"score_gpt":0.4654116590674529,"score_spread":0.3524259677951481,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}